miR-489 as a New Biomarker in Breast Cancer


Reference #: 01158


The University of South Carolina is offering licensing opportunities for a specific micro RNA (miR-489) as a new diagnostic and prognostic biomarker in breast cancer.



Breast cancer is the most commonly diagnosed cancer, and has a high rate of mortality in women. Despite aggressive clinical treatment including surgical resection, radiation, and chemotherapy, tumor recurrence is essentially universal. Breast cancer is a heterogeneous disease with several subtypes (Basal, HER2, Luminal A, Luminal B, and Normal-like subtypes) identified by unique molecular signatures. It is well documented that overexpression of HER2 promotes aggressive tumor phenotypes, increases metastasis, and decreases overall survival of patients.


Invention Description:

miR-489’s expression status in breast cancer is associated with clinical parameters and may be used to guide selection of treatments. Data indicates that the miR-489 acts as a tumor suppressor by (at least partially) targeting HER2, and represents a new prognostic biomarker and potential therapeutic target in breast cancer.


Potential Applications:

•Tumor suppression in breast cancer

•Targeted cancer treatment


Advantages and Benefits:

miR-489 is a new biomarker that can used independently or in combination with other existing biomarkers to more precisely diagnose or treat breast cancer.


Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
miRNA-489 in Treatment of Breast Cancer Utility United States 15/411,314 10,053,696 1/20/2017 8/21/2018   Issued
For Information, Contact:
Technology Commercialization
University of South Carolina
Hexin Chen
Yogin Patel
Nirav Shah
© 2024. All Rights Reserved. Powered by Inteum